https://www.biopharmawatch.com/news/AYTU/aytu-biopharma-fiscal-2026-results-report BiopharmaWatch en 2026-09-22T00:00:00.000Z Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026 https://www.biopharmawatch.com/news/OSCR/oscar-health-thrive-capital-stock-distribution BiopharmaWatch en 2026-09-19T00:31:00.000Z Oscar Health Announces Thrive Capital’s Completion of Oscar Health Common Stock Distribution to its Limited Partners https://www.biopharmawatch.com/news/VIVI/tempramed-reports-record-sales-2026 BiopharmaWatch en 2026-09-18T20:45:00.000Z TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue https://www.biopharmawatch.com/news/INM/inmed-pharmaceuticals-nasdaq-notification-shareholders-equity BiopharmaWatch en 2026-09-18T20:45:00.000Z InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance https://www.biopharmawatch.com/news/QGEN/qiagen-extraordinary-general-meeting-appointment-pratt BiopharmaWatch en 2026-09-18T20:05:00.000Z QIAGEN Calls Extraordinary General Meeting for Appointment of Jonathan M. Pratt to Managing Board https://www.biopharmawatch.com/news/CORT/corcept-chmp-recommends-approval-lifyorli BiopharmaWatch en 2026-09-18T18:58:00.000Z Riassunto: Corcept annuncia l'opinione del CHMP che raccomanda l'autorizzazione dell'UE all'immissione in commercio per Lifyorli® (relacorilant) https://www.biopharmawatch.com/news/CORT/corcept-chmp-positive-opinion-lifyorli BiopharmaWatch en 2026-09-18T18:58:00.000Z Samenvatting: Corcept kondigt positief CHMP-advies aan voor Europese markttoelating van Lifyorli® (Relacorilant) https://www.biopharmawatch.com/news/AEMD/aethlon-medical-investigation-merger-north-immunology BiopharmaWatch en 2026-09-18T18:00:00.000Z SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD) https://www.biopharmawatch.com/news/ORBS/eightco-holdings-orbs-assets-openai-beast-industries BiopharmaWatch en 2026-09-18T17:14:00.000Z Eightco Holdings (NASDAQ: ORBS) gibt einen Gesamtbestand im Wert von rund 380 Millionen US-Dollar bekannt, darunter Beteiligungen an OpenAI und Beast Industries sowie mehr als 16 000 ETH und fast 302 Millionen WLD-Token https://www.biopharmawatch.com/news/NVS/novartis-positive-chmp-opinion-cosentyx-pmr BiopharmaWatch en 2026-09-18T14:51:00.000Z Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR) https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-otc-deficiency-phase-2-update BiopharmaWatch en 2026-09-18T13:00:00.000Z Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform https://www.biopharmawatch.com/news/TCRT/alaunos-therapeutics-direct-offering-september-2026 BiopharmaWatch en 2026-09-18T13:00:00.000Z Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules https://www.biopharmawatch.com/news/SILO/silo-pharma-us-patent-allowance-spc-15-ptsd-treatment BiopharmaWatch en 2026-09-18T12:50:00.000Z Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio https://www.biopharmawatch.com/news/ONMD/onemednet-reports-record-bookings-faster-fulfillment BiopharmaWatch en 2026-09-18T12:35:00.000Z OneMedNet Reports Record Bookings as Faster Fulfillment Begins https://www.biopharmawatch.com/news/ABBV/abbvie-vraylar-real-world-data-psych-congress-2026 BiopharmaWatch en 2026-09-18T12:30:00.000Z AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026 https://www.biopharmawatch.com/news/LABT/lakewood-amendex-phase-2a-trial-nu-3-diabetic-foot-ulcers BiopharmaWatch en 2026-09-18T12:13:00.000Z Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers https://www.biopharmawatch.com/news/CORT/corcept-chmp-opinion-relacorilant-eu-authorization BiopharmaWatch en 2026-09-18T12:00:00.000Z Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) https://www.biopharmawatch.com/news/ABEO/abeona-congratulates-ultragenyx-fayuvi-approval BiopharmaWatch en 2026-09-18T11:30:00.000Z Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA) https://www.biopharmawatch.com/news/TLT/correcting-replacing-theralase-r-releases-q2-2026-financial-statements BiopharmaWatch en 2026-09-18T11:00:00.000Z Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements https://www.biopharmawatch.com/news/PODD/insulet-bernstein-healthcare-forum-2026 BiopharmaWatch en 2026-09-18T11:00:00.000Z Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum https://www.biopharmawatch.com/news/BSEM/biostem-technologies-secures-40-million-equity-facility BiopharmaWatch en 2026-09-18T11:00:00.000Z BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-09-18T11:00:00.000Z BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/JNJ/chmp-recommends-approval-tecvayli-teclistamab BiopharmaWatch en 2026-09-18T11:00:00.000Z CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-third-quarter-2026-results BiopharmaWatch en 2026-09-18T10:59:00.000Z Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026 https://www.biopharmawatch.com/news/MRK/merck-positive-eu-chmp-opinion-keytruda-padcev-mibc BiopharmaWatch en 2026-09-18T10:55:00.000Z Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) https://www.biopharmawatch.com/news/MRK/merck-launches-your-hive-of-whole-health-hiv-support BiopharmaWatch en 2026-09-18T10:45:00.000Z Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV https://www.biopharmawatch.com/news/ORBS/eightco-holdings-investments-openai-beast-industries BiopharmaWatch en 2026-09-18T10:27:00.000Z Eightco Holdings (NASDAQ: ORBS) comunica attività complessive per circa 380 milioni di dollari, comprendenti partecipazioni in OpenAI e Beast Industries, oltre 16.000 ETH e quasi 302 milioni di token WLD https://www.biopharmawatch.com/news/ORBS/eightco-holdings-nasdaq-orbs-reporta-una-tenencia-total-de-aproximadamente BiopharmaWatch en 2026-09-18T10:24:00.000Z Eightco Holdings (NASDAQ: ORBS) reporta una tenencia total de aproximadamente 380 millones de dólares https://www.biopharmawatch.com/news/NTRA/largest-mrd-study-lung-cancer-signatera BiopharmaWatch en 2026-09-18T10:00:00.000Z Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM https://www.biopharmawatch.com/news/CVS/cvs-health-redevelops-soccer-pitch-seattle-reign-fc BiopharmaWatch en 2026-09-18T08:45:00.000Z CVS Health Redevelops Soccer Pitch Alongside Seattle Reign FC and the RAVE Foundation https://www.biopharmawatch.com/news/MEDS/datameds-ai-litigation-settlement-19-million-liabilities BiopharmaWatch en 2026-09-18T06:00:00.000Z DataMeds AI Litigation Settlement Extinguishes ~$19 million In Liabilities and Retires 364,099 Common Sharessked https://www.biopharmawatch.com/news/TAK/takeda-global-csr-climate-health-systems BiopharmaWatch en 2026-09-18T05:00:00.000Z Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems https://www.biopharmawatch.com/news/HALO/halozyme-therapeutics-upsized-private-offering-convertible-notes BiopharmaWatch en 2026-09-18T03:20:00.000Z Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 https://www.biopharmawatch.com/news/LHX/lhx-investigation-alert-edelson-lechtzin-llp BiopharmaWatch en 2026-09-18T02:10:00.000Z LHX INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of L3Harris Technologies, Inc. (NYSE: LHX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm https://www.biopharmawatch.com/news/CUPR/cuprina-holdings-public-offering-closure BiopharmaWatch en 2026-09-18T01:55:00.000Z Cuprina Holdings (Cayman) Limited Announces Closing of Public Offering https://www.biopharmawatch.com/news/LINC/lincoln-educational-securities-class-action-lawsuit BiopharmaWatch en 2026-09-17T22:40:00.000Z LINCOLN EDUCATIONAL SERVICES CORP. (NASDAQ: LINC) INVESTORS: Hagens Berman Alerts Investors to Securities Class Action Lawsuit, Encourages LINC Shareholders with Losses to Contact the Firm https://www.biopharmawatch.com/news/HDB/hdb-securities-fraud-class-action-lawsuit BiopharmaWatch en 2026-09-17T22:26:00.000Z HDB ALERT: HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages HDFC Bank Limited (NYSE: HDB) Investors to Contact its Legal Team Regarding Securities Fraud Class Action Lawsuit https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-fda-review-extension-securities-class-action BiopharmaWatch en 2026-09-17T22:18:00.000Z Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline https://www.biopharmawatch.com/news/BTMD/biotech-social-advisory-board-financial-innovation BiopharmaWatch en 2026-09-17T22:17:00.000Z BioTech Social Announces Advisory Board to Advance Financial Innovation for Life Science Companies https://www.biopharmawatch.com/news/ICUI/otsuka-icumed-recall-sodium-chloride-injection BiopharmaWatch en 2026-09-17T21:08:00.000Z Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-provides-update-private-placement-3-0-million BiopharmaWatch en 2026-09-17T21:05:00.000Z Marvel Biosciences Provides Update on Private Placement for up to $3.0 Million https://www.biopharmawatch.com/news/MRVL/marvel-biosciences-private-placement-update BiopharmaWatch en 2026-09-17T21:05:00.000Z Marvel Biosciences fait le point sur un placement privé pouvant atteindre 3 millions de dollars https://www.biopharmawatch.com/news/NMAD/nomad-power-solutions-expands-business-disclosure-merger BiopharmaWatch en 2026-09-17T20:57:00.000Z NOMAD POWER SOLUTIONS FILES EXPANDED BUSINESS AND FINANCIAL DISCLOSURE FOLLOWING COMPLETION OF MERGER